Hey Neurohacker,

Thank you for tuning in. The last Signal reached a 58% open rate, and I’m genuinely grateful to everyone who reads each week. Your attention and support mean a lot.

I also want to emphasize that growing this community directly improves the quality of what I can deliver. A stronger network means better insights, more valuable content, sharper discussions, and greater opportunities for everyone involved. And honestly, seeing people engage with what I create motivates me to keep raising the standard each week and continue building something worth your time.

If you’ve found value in The NeuroCircuit, please join our Discord, share your feedback, and spread the word by sharing it with others. Every new reader strengthens what we’re building together.

✦ This Week's Partner: Accio Work

Neurotechnology News | April 11 – 17, 2026

Let's cut through the noise.

This week, Science Corporation recruited Yale's neurosurgery chair to lead its biohybrid BCI trials, and the FDA cleared Cala's next-generation tremor wearable. Meanwhile, Colorado performed its first implanted BCI surgery. Bottom line: the commercialization sprint is crowding every invasiveness tier at once.

⚡ Signal of the Week

Science Corporation onboarded Dr. Murat Günel, chair of Yale's Department of Neurosurgery, to lead U.S. human trials of its 520-electrode biohybrid cortical sensor. This stands above the rest because Science is betting on lab-grown neurons integrating with host tissue, sidestepping the gliosis and signal-drift problems that limit rigid electrode arrays. The company is skipping standard FDA approval for initial trials by placing sensors opportunistically during medically necessary craniotomies. For engineers, this is the first serious test of a "living interface" architecture in humans, and a regulatory end-run that other BCI startups will study closely.

Published: April 14, 2026
Read more ➡️ UCHealth announcement / CU Anschutz research brief

CU Anschutz and UCHealth implanted a Blackrock Neurotech array in a 41-year-old quadriplegic patient, the first such procedure in Colorado. The team placed electrodes in higher-order cognitive regions rather than motor cortex alone, as part of a Caltech/USC consortium led by Richard Andersen and Charles Liu.

💡 Big Picture: Targeting posterior parietal cortex shifts the decoding problem from movement to intent, and changes what downstream algorithms must model.

Published: April 14, 2026
Read more ➡️ TechCrunch coverage / The Next Web technical report

Max Hodak's Science Corporation recruited Dr. Murat Günel to lead U.S. human trials of its 520-electrode biohybrid cortical sensor, backed by a $230M Series C closed in March at a $1.5B valuation. Günel has said it would be "optimistic" to expect trials to begin before 2027, with sensors placed opportunistically during medically necessary craniotomies.

💡 Big Picture: Choosing opportunistic placement over a De Novo pathway trades patient throughput for faster iteration cycles, compressing the feedback loop between implant design and in-vivo behavior.

Published: April 15, 2026
Read more ➡️ PharmaShots clearance summary / Cala FDA clearance announcement

The FDA cleared Cala Health's next-generation wrist-worn neurostimulator, which uses Transcutaneous Afferent Patterned Stimulation (TAPS) for action hand tremor. Cala will present responder-rate and bilateral-tremor data at the American Academy of Neurology meeting on April 20 (poster P5-005).

💡 Big Picture: This pushes peripheral-nerve stimulation up the neurotech stack from diagnostic adjunct toward first-line prescription, bypassing the surgical bottleneck that caps DBS scale.

Science Corporation plans to skip FDA approval for initial trials by piggybacking on medically necessary craniotomies. That is clever, but it exposes a real governance gap. When a trial sensor enters a skull under the cover of a standard-of-care procedure, which IRB framework governs the implant-specific risk? And who owns the neural data captured from a patient who consented primarily to decompression? Existing IDE pathways were not designed for this opportunistic placement model.

Meet Accio Work, the agentic workspace designed to run your business operations end to end. From sourcing products and negotiating with suppliers to managing your store and launching marketing campaigns, Accio Work handles the execution so you don’t have to.

Powered by verified capabilities and deep integrations with business tools, it doesn’t just generate ideas, it takes action. Backed by Alibaba.com’s global supplier network and over 1B products, it seamlessly connects strategy to execution.

Stay in control while everything runs on autopilot.

Try One Week Free!